奥美沙坦酯治疗轻中度原发性高血压的疗效和安全性  

Clinical Efficacy and Safety of Olmesartan Medoxomil in Patients with Mild to Moderate Hypertension

作　　者：张亚文[1] 丁茹[1] 吴宗贵[1] 陈琴珍[1] 王丽娟[1] 

机构地区：[1]上海长征医院心内科

出　　处：《世界临床药物》2006年第10期585-589,共5页World Clinical Drug

摘　　要：目的评价奥美沙坦酯治疗轻中度原发性高血压的疗效和安全性。方法随机、双盲、双模拟、阳性药物(氯沙坦钾)平行对照。40例轻中度原发性高血压患者随机分为奥美沙坦酯或氯沙坦钾组,均治疗8周,观察两组治疗前后的血压、心率、心电图和血、尿常规等实验室检查结果的变化。结果奥美沙坦酯组与氯沙坦钾组比较,患者平均坐位收缩压和舒张压的降低程度均有显著性差异,分别为(18.9±8.7)mmHg和(12.6±7.6)mmHg(P<0.01);(13.8±3.5)mmHg和(11.7±3.3)mmHg(P<0.05)。治疗前后两组血压降低幅度均有显著差异,心率无明显变化。奥美沙坦酯和氯沙坦钾组降压显效率分别为63.2%和57.9%,总有效率分别为84.2%和68.4%,组间无显著差异。两组共出现3例头晕,实验室检查无异常改变。结论奥美沙坦酯治疗轻中度原发性高血压的疗效良好,不良反应发生率低。Objective To evaluate the efficacy and safety of olmesartan medoxomil administration in mild to moderate essential hypertension. Methods 40 patients were randomized into olmesartan medoxomil group or Iosartan. The changes of blood pressure, heart rate, electrocardiogram, blood and urinary laboratory examination were observed. Result Reduction in both systolic and diastolic blood pressure has significantly difference between two groups. The efficacy rates were 84.2% in olmesartan medoxomil group and 77.7% in Iosartan group. There were no change in heart rate. Adverse reactions were slight. Conclusion Olmesartan was proved to be a stable and efficacious antihypertensive medication with little adverse reactions and appears to be effective and safe for the treatment of mild to moderate hypertension.

关 键 词：奥美沙坦酯 氯沙坦钾 高血压 

分 类 号：R972.4[医药卫生—药品]